Recent advancements in the treatment of multiple myeloma have led to a notable increase in the use of bispecific antibodies in community oncology settings. This trend reflects a shift towards making innovative therapies accessible to a broader patient population. Dr. Ira Zackon, a senior medical director at Ontada, has highlighted key findings from a recent study that examines this evolving landscape.
Study Overview
A retrospective observational cohort study utilized electronic health records from the US Oncology Network to assess the uptake of bispecific antibodies among patients with relapsed or refractory multiple myeloma. The study focused on data collected between October 2022 and July 2025, following the approval of these therapies. A total of 751 patients were identified, with 405 receiving bispecific antibodies during the study period. Among these, 346 patients qualified based on the current FDA indication, requiring at least five prior lines of therapy.
Year-Over-Year Adoption Rates
The findings reveal a marked increase in the adoption of bispecific antibodies over the years. In 2022, only 5% of eligible patients received this treatment. By 2023, the figure rose to 39%, and continued to climb to 61% in 2024. As of midway through 2025, 73% of potentially eligible patients had already received bispecific therapies. This consistent year-over-year growth is encouraging, indicating that community oncology practices are increasingly integrating these therapies into their treatment protocols.
Patient Characteristics Impacting Therapy Selection
The study also examined the demographics of patients receiving bispecific antibodies. It found that patients in community settings tended to be slightly older than those in clinical trials, with an average age of 72 compared to less than 70 in trial populations. Additionally, patients receiving bispecific therapies generally exhibited better performance status, with fewer individuals having compromised daily functioning.
Logistical Considerations for Patients
Implementing bispecific antibody therapy in outpatient settings presents logistical challenges. The need for caregiver support, transportation, and other social determinants can impact a patient’s ability to access these therapies. Recognizing these barriers is crucial for optimizing treatment delivery and ensuring that patients receive the care they need.
The Importance of Community Access
The rise of bispecific antibodies in community oncology is significant for several reasons. First, it demonstrates the potential for innovative treatments to reach a wider audience, particularly in settings outside academic hospitals. Ensuring that patients have access to these therapies is vital for maximizing their benefits and improving overall outcomes in multiple myeloma treatment.
Future Directions in Bispecific Antibody Research
The study opens avenues for further research into the long-term effects of bispecific antibodies and their role in varying patient populations. Understanding how factors such as age, performance status, and logistical support influence treatment outcomes will be critical for optimizing therapy selection and delivery.
Conclusion
The increasing adoption of bispecific antibodies in community oncology marks a positive shift in the management of multiple myeloma. By addressing logistical challenges and enhancing access to these therapies, healthcare providers can significantly impact patient outcomes. As the landscape of cancer treatment continues to evolve, ongoing research and community engagement will be key to ensuring that patients benefit from the latest advancements in therapy.
- Takeaway Points:
- Bispecific antibodies are becoming more prevalent in community oncology for multiple myeloma.
- Patient demographics in community settings differ from those in clinical trials.
- Logistical support is crucial for patient access to bispecific therapies.
- Continued research is needed to optimize treatment strategies.
- Community engagement is essential for enhancing patient outcomes.
Read more → www.ajmc.com